147 related articles for article (PubMed ID: 33462345)
21. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
Narasimhalu K; Ang YK; Tan DSY; De Silva DA; Tan KB
Clin Drug Investig; 2020 Nov; 40(11):1063-1070. PubMed ID: 32959334
[TBL] [Abstract][Full Text] [Related]
22. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.
Crespin DJ; Federspiel JJ; Biddle AK; Jonas DE; Rossi JS
Value Health; 2011 Jun; 14(4):483-91. PubMed ID: 21669373
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Sorich MJ; Horowitz JD; Sorich W; Wiese MD; Pekarsky B; Karnon JD
Pharmacogenomics; 2013 Dec; 14(16):2013-21. PubMed ID: 24279856
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Micieli A; Singh N; Jahn B; Siebert U; Menon BK; Demchuk AM
Int J Stroke; 2023 Apr; 18(4):416-425. PubMed ID: 35739635
[TBL] [Abstract][Full Text] [Related]
25. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
26. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Janzon M; James S; Cannon CP; Storey RF; Mellström C; Nicolau JC; Wallentin L; Henriksson M
Heart; 2015 Jan; 101(2):119-25. PubMed ID: 25227704
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E
Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
29. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Gasche D; Ulle T; Meier B; Greiner RA
Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
[TBL] [Abstract][Full Text] [Related]
31. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Cowper PA; Pan W; Anstrom KJ; Kaul P; Wallentin L; Davidson-Ray L; Nikolic E; Janzon M; Levin LÅ; Cannon CP; Harrington RA; Mark DB
J Am Coll Cardiol; 2015 Feb; 65(5):465-76. PubMed ID: 25660925
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
[TBL] [Abstract][Full Text] [Related]
33. Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack.
Narasimhalu K; Chan J; Ang YK; De Silva DA; Tan KB
Int J Stroke; 2024 Feb; 19(2):209-216. PubMed ID: 37679898
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Theidel U; Asseburg C; Giannitsis E; Katus H
Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
Cai Z; Cai D; Wang R; Wang H; Yu Z; Gao F; Liu Y; Kang Y; Wu Z
Sci Rep; 2021 Apr; 11(1):7383. PubMed ID: 33795788
[TBL] [Abstract][Full Text] [Related]
36. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
Coleman CI; Limone BL
Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
[TBL] [Abstract][Full Text] [Related]
37. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
Thi Thu Nguyen T; Van Do D; Mellstrom C; Quang Nguyen T; Manh Pham H; Van Hoang S; Cong Luu T; Le Phuong T
Adv Ther; 2021 Jul; 38(7):4026-4039. PubMed ID: 34115329
[TBL] [Abstract][Full Text] [Related]
39. Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Wu B; Tobe RG; Liu Y; He B
Clin Drug Investig; 2018 Jul; 38(7):621-630. PubMed ID: 29713921
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Nikolic E; Janzon M; Hauch O; Wallentin L; Henriksson M;
Eur Heart J; 2013 Jan; 34(3):220-8. PubMed ID: 22719022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
